 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 April 2004 | Volume 140 Issue 8 | Pages 650-658
Background: Cardiovascular disease is the primary complication and cause of death in patients with type 2 diabetes mellitus. Modification of cardiovascular risk factors may improve patient outcomes.
Purpose: To evaluate the effectiveness of pharmacologic lipid-lowering therapy on outcomes in type 2 diabetes mellitus.
Data Sources: Review of the literature.
Study Selection: Randomized trials evaluating clinical outcomes of lipid-lowering treatment in patients with diabetes.
Data Extraction: Studies were identified by searching the Cochrane Library, MEDLINE, meta-analyses, review articles, and inquiries to experts. The Cochrane Library and MEDLINE searches were done in September 2002. Data were abstracted onto standardized forms by a single reviewer and were confirmed by a second reviewer.
Data Synthesis: Meta-analysis of 6 primary prevention studies showed that lipid-lowering medications reduced risks for cardiovascular outcomes (relative risk, 0.78 [95% CI, 0.67 to 0.89]; absolute risk reduction, 0.03 [CI, 0.01 to 0.04] in 4.3 years of treatment); 1 major cardiovascular event was prevented by treating 34 to 35 patients. Meta-analysis of 8 studies of secondary prevention showed a similar relative risk (0.76 [CI, 0.59 to 0.93]) but more than twice the absolute risk reduction (0.07 [CI, 0.03 to 0.12] in 4.9 years of treatment) and a number needed to treat for benefit of 13 to 14. Most studies compared a lipid-lowering drug with placebo but did not evaluate the effect of reaching specific cholesterol levels. The benefit of lipid lowering with a fixed dose of a statin appeared to be similar regardless of starting cholesterol levels.
Limitations: Target cholesterol levels and the effectiveness of dose titration (or the use of multiple agents) have not been rigorously examined.
Conclusions: In patients with type 2 diabetes, treatment with lipid-lowering agents reduces cardiovascular risk. Most patients, including those whose baseline low-density lipoprotein cholesterol levels are below 2.97 mmol/L (<115 mg/dL), and possibly below 2.59 mmol/L (<100 mg/dL), benefit from statins. Moderate doses of these drugs suffice in most patients with diabetes.
Author and Article Information
From the Veterans Affairs Health Services Research and Development Center for Practice Management and Outcomes Research, University of Michigan, and the Michigan Diabetes Research and Training Center, Ann Arbor, Michigan.
Grant Support: Dr. Vijan is a Veterans Affairs Health Services Research and Development Career Development Awardee. The American College of Physicians provided an honorarium to the authors for conducting this review. This funding had no role in the design, conduct, and reporting of this review.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Sandeep Vijan, MD, MS, Veterans Affairs Health Services Research and Development, 2215 Fuller Road, Mailstop 11H, Ann Arbor, MI 48105; e-mail, svijan{at}umich.edu.
Current Author Addresses: Drs. Vijan and Hayward: Veterans Affairs Health Services Research and Development, 2215 Fuller Road, Mailstop 11H, Ann Arbor, MI 48105. CLINICAL GUIDELINES
Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. L. Peters Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes Clin. Diabetes, January 1, 2008; 26(1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Riche and K. S. McClendon Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus Am. J. Health Syst. Pharm., August 1, 2007; 64(15): 1603 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Harris A 52-Year-Old Woman With Hypertension and Diabetes Who Presents With Chest Pain Clin. Diabetes, July 1, 2007; 25(3): 115 - 118. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tunceli, C. J. Bradley, J. E. Lafata, M. Pladevall, G. W. Divine, A. C. Goodman, and S. Vijan Glycemic Control and Absenteeism Among Individuals With Diabetes Diabetes Care, May 1, 2007; 30(5): 1283 - 1285. [Full Text] [PDF]
|
|
|
|
 |
|
 Statins OK for Most to Reduce MI Risk DOC News, April 1, 2007; 4(4): 4 - 4. [Full Text]
|
|
|
|
|
|
D. Rucker, J. A. Johnson, T.K. Lee, D. T. Eurich, R. Z. Lewanczuk, S. H. Simpson, E. L. Toth, and S. R. Majumdar The Natural History of LDL Control in Type 2 Diabetes: A prospective study of adherence to lipid guidelines. Diabetes Care, November 1, 2006; 29(11): 2506 - 2508. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hayward, T. P. Hofer, and S. Vijan Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med, October 3, 2006; 145(7): 520 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y F Wu, W. Y S Leung, S. Chang, B. Lee, B. Zee, P. C Y Tong, and J. C N Chan Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial BMJ, September 9, 2006; 333(7567): 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Molitch Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Costa, M. Borges, C. David, and A. Vaz Carneiro Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials BMJ, May 13, 2006; 332(7550): 1115 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q Wan, M F Harris, U W Jayasinghe, J Flack, A Georgiou, D L Penn, and J R Burns Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. Qual. Saf. Health Care, April 1, 2006; 15(2): 131 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wartofsky Update in Endocrinology Ann Intern Med, November 1, 2005; 143(9): 673 - 682. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wilson, S. Gilliland, T. Cullen, K. Moore, Y. Roubideaux, L. Valdez, W. Vanderwagen, and K. Acton Diabetes Outcomes in the Indian Health System During the Era of the Special Diabetes Program for Indians and the Government Performance and Results Act Am J Public Health, September 1, 2005; 95(9): 1518 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Veiraiah Hyperglycemia, Lipoprotein Glycation, and Vascular Disease Angiology, July 1, 2005; 56(4): 431 - 438. [Abstract] [PDF]
|
|
|
|
|
|
E. D. Beishuizen, J. T. Tamsma, J. W. Jukema, M. A. van de Ree, J. C. M. van der Vijver, A. E. Meinders, and M. V. Huisman The Effect of Statin Therapy on Endothelial Function in Type 2 Diabetes Without Manifest Cardiovascular Disease Diabetes Care, July 1, 2005; 28(7): 1668 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Brown Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F34 - F40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Krein, M. Heisler, J. D. Piette, F. Makki, and E. A. Kerr The Effect of Chronic Pain on Diabetes Patients' Self-Management Diabetes Care, January 1, 2005; 28(1): 65 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Beishuizen, M. A. van de Ree, J. W. Jukema, J. T. Tamsma, J. C. M. van der Vijver, A. E. Meinders, H. Putter, and M. V. Huisman Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease Diabetes Care, December 1, 2004; 27(12): 2887 - 2892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB Evid. Based Med., November 1, 2004; 9(6): 163 - 163. [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Stone Stopping Statins Circulation, October 19, 2004; 110(16): 2280 - 2282. [Full Text] [PDF]
|
|
|
|
 |
|
 23 Apr 2004 to 23 Jul 2004 Evid. Based Nurs., October 1, 2004; 7(4): e4 - e4. [Full Text] [PDF]
|
|
|
|
 |
|
 ACP Recommends Lipid-lowering Therapy for Primary and Secondary Prevention of CHD in Type 2 Diabetes Journal Watch (General), May 7, 2004; 2004(507): 4 - 4. [Full Text]
|
|
|
|
|
|
V. Snow, M. D. Aronson, E. R. Hornbake, C. Mottur-Pilson, K. B. Weiss, and the Clinical Efficacy Assessment Subcommittee of t Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, April 20, 2004; 140(8): 644 - 649. [Abstract] [Full Text] [PDF]
|
|
Article
